CoChat
Sign Up
Cited by 123Alzheimer's disease research and treatmentsMolecular Sensors and Ion DetectionLuminescence and Fluorescent Materials

The DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.

Turn-on chemiluminescence probes and dual-amplification of signal for detection of amyloid beta species in vivo

Open access
Yang, Jing, Yin, Wei, Van, Richard, Yin, Keyi, Wang, Peng, Zheng, Chao, Zhu, Biyue, Ran, Kathleen, Zhang, Can, Kumar, Mohanraja, Shao, Yihan, Ran, Chongzhao·2020·Nature Communications
DOI 10.1038/s41467-020-17783-4PMC PMC7426431

Published version of a preprint

Open this paper in CoChat — free accountOpen PDF

Abstract

Turn-on fluorescence imaging is routinely studied; however, turn-on chemiluminescence has been rarely explored for in vivo imaging. Herein, we report the design and validation of chemiluminescence probe ADLumin-1 as a turn-on probe for amyloid beta (Aβ) species. Two-photon imaging indicates that ADLumin-1 can efficiently cross the blood–brain barrier and provides excellent contrast for Aβ plaques and cerebral amyloid angiopathy. In vivo brain imaging shows that the chemiluminescence signal of ADLumin-1 from 5-month-old transgenic 5xFAD mice is 1.80-fold higher than that from the age-matched wild-type mice. Moreover, we demonstrate that it is feasible to further d ually- a mplify s ignal via c hemiluminescence r esonance e nergy t ransfer (DAS-CRET) using two non-conjugated smart probes (ADLumin-1 and CRANAD-3) in solutions, brain homogenates, and in vivo whole brain imaging. Our results show that DAS-CRET can provide a 2.25-fold margin between 5-month-old 5xFAD mice and wild type mice. We believe that our strategy could be extended to other aggregating-prone proteins.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-020-17783-4

Cites

73 of 73 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Design and synthesis of ADLumin-1. a Diagram of designing of chemiluminescent probes that contain moiety A for generating chemiluminescence (green) and moiety B for binding to Aβs; b Chemical structures of the designed probes ADLumin-X (X = −1 and −2) and diagram for illustrating turn-on with ADLumin-X in the presence of Aβs; c) Synthetic route of ADLumin-Xs. Reagents and conditions: (I) TMP, n-BuLi, THF; (II) 5-bromo-2-aminopyrazine, Pd(PPh3)4, NaCO3 aq, 1,4-dioxane; (III) Methylglyoxal 1,1-dimethyl acetal, EtOH, HCl aq.
Fig. 1 Design and synthesis of ADLumin-1. a Diagram of designing of chemiluminescent probes that contain moiety A for generating chemiluminescence (green) and moiety B for binding to Aβs; b Chemical structures of the designed probes ADLumin-X (X = −1 and −2) and diagram for illustrating turn-on with ADLumin-X in the presence of Aβs; c) Synthetic route of ADLumin-Xs. Reagents and conditions: (I) TMP, n-BuLi, THF; (II) 5-bromo-2-aminopyrazine, Pd(PPh3)4, NaCO3 aq, 1,4-dioxane; (III) Methylglyoxal 1,1-dimethyl acetal, EtOH, HCl aq.CC BY · PubMed Central
Fig. 2 In vitro characterization of chemiluminescence properties of ADLumin-1. a Chemiluminescence spectrum of ADLumin-1 in DMSO; b Quantitative analysis of chemiluminescence intensity of ADLumin-1 in DMSO solutions before and after stirring. Representative images were inserted. c Quantification of chemiluminescence intensity of ADLumin-1 with (red) or without (black) bubbled oxygen; d LC-MS spectra of ADLumin-1 and ADLumin-3 (the oxidation product). Note: ADLumin-1 (t = 3.05 min), ADLumin-3 (t = 3.85 min); e Proposed oxygen-dependent mechanism of ADLumin-1 for chemiluminescence generation. Data are represented as mean ± s.d. with n = 3 biologically independent samples. P = 0.0009 (b). The P-values were generated by Graphpad Prism 8 with two-tailed unpaired t-test; ***P-value < 0.001; Source data underlying b and c are provided as Source Data file.
Fig. 2 In vitro characterization of chemiluminescence properties of ADLumin-1. a Chemiluminescence spectrum of ADLumin-1 in DMSO; b Quantitative analysis of chemiluminescence intensity of ADLumin-1 in DMSO solutions before and after stirring. Representative images were inserted. c Quantification of chemiluminescence intensity of ADLumin-1 with (red) or without (black) bubbled oxygen; d LC-MS spectra of ADLumin-1 and ADLumin-3 (the oxidation product). Note: ADLumin-1 (t = 3.05 min), ADLumin-3 (t = 3.85 min); e Proposed oxygen-dependent mechanism of ADLumin-1 for chemiluminescence generation. Data are represented as mean ± s.d. with n = 3 biologically independent samples. P = 0.0009 (b). The P-values were generated by Graphpad Prism 8 with two-tailed unpaired t-test; ***P-value < 0.001; Source data underlying b and c are provided as Source Data file.CC BY · PubMed Central
Fig. 3 In vitro characterization of fluorescence and chemiluminescence properties of ADLumin-1 in the presence of Aβs. a Fluorescence spectra of ADLumin-1 alone (red) and with Aβ40 aggregates (black); b Chemiluminescence spectra of ADLumin-1 alone (red) and with Aβ40 aggregates (black); c Molecule docking of ADLumin-1 (blue) with Aβ fibrils (PDB:5OQV). d In vitro chemiluminescence images of ADLumin-1 alone and with Aβ40 aggregates in PBS. e Quantification of chemiluminescence intensity in d. f In vitro chemiluminescence images of ADLumin-1 alone and with Aβ40 aggregates in mouse brain homogenate; g Quantification of chemiluminescence intensity in f. Data are represented as mean ± s.d. with n = 3 biologically independent samples. P = 0.0005 (e), P < 0.0001 (g). The P-values were generated by Graphpad Prism 8 with two-tailed unpaired t-test; ***P-value < 0.001, ****P-value < 0.0001. Source data underlying e and g are provided as Source Data file.
Fig. 3 In vitro characterization of fluorescence and chemiluminescence properties of ADLumin-1 in the presence of Aβs. a Fluorescence spectra of ADLumin-1 alone (red) and with Aβ40 aggregates (black); b Chemiluminescence spectra of ADLumin-1 alone (red) and with Aβ40 aggregates (black); c Molecule docking of ADLumin-1 (blue) with Aβ fibrils (PDB:5OQV). d In vitro chemiluminescence images of ADLumin-1 alone and with Aβ40 aggregates in PBS. e Quantification of chemiluminescence intensity in d. f In vitro chemiluminescence images of ADLumin-1 alone and with Aβ40 aggregates in mouse brain homogenate; g Quantification of chemiluminescence intensity in f. Data are represented as mean ± s.d. with n = 3 biologically independent samples. P = 0.0005 (e), P < 0.0001 (g). The P-values were generated by Graphpad Prism 8 with two-tailed unpaired t-test; ***P-value < 0.001, ****P-value < 0.0001. Source data underlying e and g are provided as Source Data file.CC BY · PubMed Central
Fig. 4 Chemiluminescence light penetration of ADLumin-1. a Chemiluminescence spectra of ADLumin-1 (black) and bioluminescence spectra of Luciferin (red); b Light penetration study with Luciferin and ADLumin-1. A glass tube filled with a solution of firefly luciferin with luciferase or ADLumin-1 with similar intensities before putting under the abdomen of two nude mice; c Images that were captured from the dorsal side with an IVIS imaging system after placing the tubes; d The quantification of the penetrated light in c. Nearly 5% light penetrated the whole body in both groups.
Fig. 4 Chemiluminescence light penetration of ADLumin-1. a Chemiluminescence spectra of ADLumin-1 (black) and bioluminescence spectra of Luciferin (red); b Light penetration study with Luciferin and ADLumin-1. A glass tube filled with a solution of firefly luciferin with luciferase or ADLumin-1 with similar intensities before putting under the abdomen of two nude mice; c Images that were captured from the dorsal side with an IVIS imaging system after placing the tubes; d The quantification of the penetrated light in c. Nearly 5% light penetrated the whole body in both groups.CC BY · PubMed Central
Fig. 5 In vitro and in vivo plaques imaging with ADLumin-1. a Representative brain slice image of cortex area of a 24-mo-old APP/PS1 mouse with ADLumin-1 staining; b Two-photon microscopic image of brain cortex area with ADLumin-1 in an alive 15-mo-old 5xFAD mouse. The blood vessels were highlighted by Rhodamine B isothiocyanate-Dextran, and the presentative image is merged images from two concurrent imaging channels. The yellow arrows indicate plaques, and the white arrows indicate CAA labeling; Scale bar: 50 μm. c Ex vivo histology of a mouse brain slice obtained after the two-photon imaging with ADLumin-1. d–f Quantitative analysis of SNR of plaques of in vitro slice (d) (mean ± s.d., n = 6 independent measurements), in vivo plaques (mean ± s.d., n = 5 independent measurements) and CAAs (mean ± s.d., n = 5 independent measurements) (e), and ex vivo plaques (mean ± s.d., n = 6 independent measurements) (f). P < 0.0001 (d); P < 0.0001 (e); and P < 0.0001 (f). The P-values were generated by Graphpad Prism 8 with two-tailed unpaired t-test; ***P-value < 0.001, ****P-value < 0.0001. Bkg background, CAA cerebral amyloid angiopathy. Source data underlying d–f are provided as Source Data file.
Fig. 5 In vitro and in vivo plaques imaging with ADLumin-1. a Representative brain slice image of cortex area of a 24-mo-old APP/PS1 mouse with ADLumin-1 staining; b Two-photon microscopic image of brain cortex area with ADLumin-1 in an alive 15-mo-old 5xFAD mouse. The blood vessels were highlighted by Rhodamine B isothiocyanate-Dextran, and the presentative image is merged images from two concurrent imaging channels. The yellow arrows indicate plaques, and the white arrows indicate CAA labeling; Scale bar: 50 μm. c Ex vivo histology of a mouse brain slice obtained after the two-photon imaging with ADLumin-1. d–f Quantitative analysis of SNR of plaques of in vitro slice (d) (mean ± s.d., n = 6 independent measurements), in vivo plaques (mean ± s.d., n = 5 independent measurements) and CAAs (mean ± s.d., n = 5 independent measurements) (e), and ex vivo plaques (mean ± s.d., n = 6 independent measurements) (f). P < 0.0001 (d); P < 0.0001 (e); and P < 0.0001 (f). The P-values were generated by Graphpad Prism 8 with two-tailed unpaired t-test; ***P-value < 0.001, ****P-value < 0.0001. Bkg background, CAA cerebral amyloid angiopathy. Source data underlying d–f are provided as Source Data file.CC BY · PubMed Central
Fig. 6 In vivo chemiluminescence imaging with ADLumin-1. a In vivo brain imaging of WT and 5XFAD mice with iv injection of ADLumin-1; b Quantitative analysis of the images in a; c Representative images of eyes in WT and 5xFAD mice after iv injection with ADLumin-1; d Quantitative analysis of the images in c (n = 4). Error bar: Stdev; Data points with its error bar stands for mean ± s.d. derived from n = 4 biologically independent animals. P < 0.0001 (b); P = 0.0098 (d). The P-values were generated by Graphpad Prism 8 with two-tailed unpaired t-test; ***P-value < 0.001; **P-value < 0.01. AD Alzheimer’s disease, WT wild-type. Source data underlying b and d are provided as Source Data file.
Fig. 6 In vivo chemiluminescence imaging with ADLumin-1. a In vivo brain imaging of WT and 5XFAD mice with iv injection of ADLumin-1; b Quantitative analysis of the images in a; c Representative images of eyes in WT and 5xFAD mice after iv injection with ADLumin-1; d Quantitative analysis of the images in c (n = 4). Error bar: Stdev; Data points with its error bar stands for mean ± s.d. derived from n = 4 biologically independent animals. P < 0.0001 (b); P = 0.0098 (d). The P-values were generated by Graphpad Prism 8 with two-tailed unpaired t-test; ***P-value < 0.001; **P-value < 0.01. AD Alzheimer’s disease, WT wild-type. Source data underlying b and d are provided as Source Data file.CC BY · PubMed Central
Fig. 7 In vitro validation of CRET with ADLumin-1/CRANAD-3 pair. a Proposed CRET model between ADLumin-1 and CRANAD-3 with Aβ40 fibrils. Two nonconjugated molecules upon binding to fibrils to bring ADLumin-1 (Donor) close enough to CRANAD-3 (Acceptor) to initiate CRET; b Spectrum of the CRET pair with Aβ40 fibrils in PBS (red line), and the peak was consistent with the emission of CRANAD-3 in the presence of Aβ40 fibrils. Chemiluminescence spectrum of ADLumin-1 with Aβ40 fibrils (black line); and spectrum of the mixture of ADLumin-1 and CRANAD-3 without Aβ40 fibrils (pink line). The FRETing efficiency was very high, evident by the low intensity at 500–560 nm range; c Spectrum of the CRET pair in brain homogenate (red line), evident by a decrease in ADLumin-1 emission (black line) and increase in CRANAD-3 emission; d Spectral unmixing of DAS-CRET to separate the contribution from ADLumin-1 only (Unmixed #1), and CRET (Unmixed #2) and CRANAD-3 only (Unmixed #3).
Fig. 7 In vitro validation of CRET with ADLumin-1/CRANAD-3 pair. a Proposed CRET model between ADLumin-1 and CRANAD-3 with Aβ40 fibrils. Two nonconjugated molecules upon binding to fibrils to bring ADLumin-1 (Donor) close enough to CRANAD-3 (Acceptor) to initiate CRET; b Spectrum of the CRET pair with Aβ40 fibrils in PBS (red line), and the peak was consistent with the emission of CRANAD-3 in the presence of Aβ40 fibrils. Chemiluminescence spectrum of ADLumin-1 with Aβ40 fibrils (black line); and spectrum of the mixture of ADLumin-1 and CRANAD-3 without Aβ40 fibrils (pink line). The FRETing efficiency was very high, evident by the low intensity at 500–560 nm range; c Spectrum of the CRET pair in brain homogenate (red line), evident by a decrease in ADLumin-1 emission (black line) and increase in CRANAD-3 emission; d Spectral unmixing of DAS-CRET to separate the contribution from ADLumin-1 only (Unmixed #1), and CRET (Unmixed #2) and CRANAD-3 only (Unmixed #3).CC BY · PubMed Central
Fig. 8 Observation of CRET under in vivo mimic conditions. a A mixture of ADLumin-1 and CRANAD-3 with Aβ40 aggregates (CRET + Aβ) were injected subcutaneously into the right inner thigh of a female nude mouse and the control group of ADLumin-1+Aβ was injected into the left side; b The mouse was imaged from both the ventral and dorsal sides; c Spectral unmixing was conducted with sequence imaging at 15 min post injection to separate signals from ADLumin-1 (left, green) and from CRET pair (middle, red), and composite image of the two unmixed components (right); D Spectra of the unmixed contributors, ADLumin-1+Aβ (green), and CRET + Aβ (red).
Fig. 8 Observation of CRET under in vivo mimic conditions. a A mixture of ADLumin-1 and CRANAD-3 with Aβ40 aggregates (CRET + Aβ) were injected subcutaneously into the right inner thigh of a female nude mouse and the control group of ADLumin-1+Aβ was injected into the left side; b The mouse was imaged from both the ventral and dorsal sides; c Spectral unmixing was conducted with sequence imaging at 15 min post injection to separate signals from ADLumin-1 (left, green) and from CRET pair (middle, red), and composite image of the two unmixed components (right); D Spectra of the unmixed contributors, ADLumin-1+Aβ (green), and CRET + Aβ (red).CC BY · PubMed Central
Fig. 9 In vivo DAS-CRET imaging. a In vivo brain imaging of WT and 5XFAD mice with mixture of ADLumin-1 and CRANAD-3; b In vivo emission spectra of CRET pair (red line-5xFAD) and control (black line-WT), and ADLumin-1 only (pink line-5xFAD) and ADLumin-1 only control (blue line-WT); c–e Quantitative analysis of the images with CRET pair with the setting of open filter (c), at 640 nm (d) and after spectral unmixing (e). Data are represented as mean ± s.d. with n = 3 biologically independent animals. P = 0.0059 (c), P = 0.0292 (d), P = 0.0133 (e). The P-values were generated by Graphpad Prism 8 with two-tailed unpaired t-test; *P-value < 0.05, **P-value < 0.01. Source data underlying c–e are provided as Source Data file.
Fig. 9 In vivo DAS-CRET imaging. a In vivo brain imaging of WT and 5XFAD mice with mixture of ADLumin-1 and CRANAD-3; b In vivo emission spectra of CRET pair (red line-5xFAD) and control (black line-WT), and ADLumin-1 only (pink line-5xFAD) and ADLumin-1 only control (blue line-WT); c–e Quantitative analysis of the images with CRET pair with the setting of open filter (c), at 640 nm (d) and after spectral unmixing (e). Data are represented as mean ± s.d. with n = 3 biologically independent animals. P = 0.0059 (c), P = 0.0292 (d), P = 0.0133 (e). The P-values were generated by Graphpad Prism 8 with two-tailed unpaired t-test; *P-value < 0.05, **P-value < 0.01. Source data underlying c–e are provided as Source Data file.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

Sorted by citations

See all 123

Related

See all

Metadata

Authors
Yang, J., Yin, W., Van, R., Yin, K., Wang, P., Zheng, C., Zhu, B., Ran, K., Zhang, C., Kumar, M., Shao, Y., & Ran, C.
Affiliations
  • Harvard University (US)
  • University of Oklahoma (US)
  • Massachusetts Institute of Technology (US)
Corresponding author
Ran, Chongzhao
ORCID
Venue
Nature Communications
Publisher
Springer Science and Business Media LLC
Published
2020-08-13
Volume
11
Issue
1
Pages
4052-4052
ISSN
2041-1723 (ISSN-L)
DOI
10.1038/s41467-020-17783-4
PMC
PMC7426431
OpenAlex
W3048903908
Cited by
123
References
73
Citations by year
2026: 16 · 2025: 16 · 2024: 24 · 2023: 24 · 2022: 13 · 2021: 27 · 2020: 3
FWCI
10.07
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • ChemRxiv (acceptedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by-nc-nd)
Funders
U.S. Department of Health & Human Services | NIH | National Institute on Aging (R21AG059134, R01AG055413)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Physical Sciences › Chemistry › Spectroscopy › Molecular Sensors and Ion Detection
  • Physical Sciences › Materials Science › Materials Chemistry › Luminescence and Fluorescent Materials
Keywords
chemiluminescence probe, amyloid-beta detection, chemiluminescence resonance energy transfer, two-photon imaging, blood-brain barrier penetration, cerebral amyloid angiopathy, amyloid plaques, 5xFAD mice, in vivo brain imaging
MeSH terms
Animals, Luminescent Measurements, Amyloid beta-Peptides, Luminescence, Mice, Molecular Imaging, Optical Imaging, Protein Aggregates

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review